Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUCCESS: Empaveli in Acute Ischemic Stroke
NCT07495722Phase 1Not yet recruiting
- Sponsor
- Columbia University
- Start
- Oct 2026
- Primary completion
- Apr 2027
- Modality
- PEGylated Peptides
01
Overview
Phase 1, open-label, single-arm trial of pegcetacoplan in ischemic stroke, sponsored by Columbia University. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 90 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
pegcetacoplan
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07495722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495722.